Interview with Paul Flapper, General Manager, Shire International Licensing BV…
Shire has many offices in America, Europe, as well as in Singapore, in Japan and in Australia. The group has a vast global network and a strong presence in these…
Address: Strawinskylaan six hundred fifty-nine
1 077 XX Amsterdam
,Netherlands
Tel: +31 (0) 20 364 00 74
Web: http://www.shirenederland.nl/
Shire is a global specialty biopharmaceutical company founded in 1986. Shire aims those with life-limiting illnesses helping a better life.
Shire seeks to achieve this through multiple therapeutic areas in medicine specialist to develop, produce and sell. Shire’s activities are housed in two divisions:
‘Human Genetic Therapies’ focused on genetic diseases such as Hunter syndrome, Fabry disease and hereditary angioedema.
Specialty Products’ represents the therapeutic areas of ADHD, Nephrology, Hematology and Gastroenterology.
Shire group is structured as two autonomous businesses supported by global corporate functions; business unit structure that enables small molecule entities to thrive under Shire Specialty Pharma and protein therapeutics to emerge from Shire Human Genetic Therapies
Shire Human Genetics Therapies delivers medicine in the therapeutic area lysosomal storage diseases, namely Fabry disease and Hunter syndrome.
Shire has many offices in America, Europe, as well as in Singapore, in Japan and in Australia. The group has a vast global network and a strong presence in these…
Bart van de Kerkhof highlights how Covidien’s acquisition will drive Medtronic to new heights thanks to a broader product portfolio. Medtronic is already piloting projects and cooperating with key stakeholders to…
Anita Atema, General Manager of Celgene, reveals Celgene’s inspiring and concrete initiatives that illustrate how a true willingness to cooperate with healthcare stakeholders and a remarkable effort of transparency can help…
Amgen Netherlands is preparing to launch five new products next year, including their leading cardiovascular biotech product Repatha and recently announced the acquisition of the Dutch biotech Dezima. General manager…
Maikel Beerens, CEO and founder of Xilloc, a promising Dutch company that designs patient-specific implants, anatomical models and surgical guides for bone reconstruction or augmentation with the help of 3-D…
Michiel van der Veen, CEO of GenKey, a global player in biometric identity management based in Eindhoven, explains how both the healthcare industry and public health schemes could benefit from…
Menno Kok and Roel Kamerling, Director and CIO of Medical Delta, a life sciences, health & technology innovation cluster around Leiden, Delft and Rotterdam in the West of the Netherlands,…
Bert de Jong, General Manager Benelux at Genzyme, discusses the solutions Genzyme is offering to patients suffering from rare diseases and MS in the Benelux and how these treatments add value overall…
Roche Netherlands General Manager Bart Vanhauwere explains how the company has managed to foster growth at the Dutch affiliate thanks to its long-term strategic vision and the collaborative approach it…
Europe’s longest-standing Minister of Health, Edith Schippers, provides insight into the local healthcare system and continued efforts to improve quality of life for Dutch citizens, as well as revealing the…
Sean Connor, General Manager Benelux and UK/ROI for ALK, details the company’s strategy both in terms of products and therapeutic areas and provides us with his assessment of Netherlands regulatory…
A well-established player in the Allergy market, the Dutch company HAL Allergy recently expanded its activities with the addition of its HALIX Contract Manufacturing Outsourcing (CMO) arm. CEO Harry Flore…
With almost thirty years of experience in the life sciences sector, local Dutch consultancy firm Baggerman Farma Consult offers a wide portfolio of services to its clients in the pharmaceutical…
See our Cookie Privacy Policy Here
